A phase 2 clinical trial showed topical ocular reproxalap to be non-inferior to Pred Forte in patients with noninfectious anterior uveitis, Aldeyra Therapeutics announced in a press release.
The randomized, multicenter, investigator-masked, comparator-controlled, parallel-group trial found reproxalap 0.5%, an aldehyde sequestering agent, was non-inferior to Pred Forte (prednisolone, Allergan) after 2 weeks (P = .036) and 4 weeks (P = .048) in reducing anterior chamber inflammatory cell count.
A combination of reproxalap and twice-daily Pred Forte was also statistically non-inferior to
Uncategorized